Bausch Health Cos Inc. (NYSE:BHC) Receives Consensus Rating of “Reduce” from Analysts

Bausch Health Cos Inc. (NYSE:BHC) has been given an average rating of “Reduce” by the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $8.00.

Several research analysts recently weighed in on the company. Zacks Research upgraded Bausch Health Cos from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Finally, Weiss Ratings upgraded Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st.

Bausch Health Cos Price Performance

Bausch Health Cos stock opened at $6.31 on Monday. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. The company has a 50-day moving average price of $5.53 and a 200 day moving average price of $5.49. Bausch Health Cos has a 12-month low of $4.33 and a 12-month high of $8.00. The stock has a market cap of $2.36 billion, a P/E ratio of -2.13 and a beta of 0.38.

Bausch Health Cos (NYSE:BHC) last posted its earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.30. The company had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. Sell-side analysts anticipate that Bausch Health Cos will post 4.35 earnings per share for the current year.

Insiders Place Their Bets

In other Bausch Health Cos news, insider Aimee J. Lenar sold 36,827 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total transaction of $258,893.81. Following the completion of the transaction, the insider owned 334,853 shares of the company’s stock, valued at $2,354,016.59. This trade represents a 9.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Bausch Health Cos

Several large investors have recently made changes to their positions in BHC. Tidal Investments LLC raised its holdings in Bausch Health Cos by 2.6% in the second quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock valued at $334,000 after acquiring an additional 1,276 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in Bausch Health Cos by 14.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock valued at $98,000 after acquiring an additional 1,812 shares during the last quarter. Jones Financial Companies Lllp acquired a new stake in shares of Bausch Health Cos during the second quarter worth about $148,000. Pictet Asset Management Holding SA lifted its holdings in shares of Bausch Health Cos by 4.1% in the 1st quarter. Pictet Asset Management Holding SA now owns 54,169 shares of the company’s stock valued at $292,000 after purchasing an additional 2,114 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in shares of Bausch Health Cos by 2.5% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock valued at $690,000 after purchasing an additional 2,552 shares during the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.